Ottawa researchers have developed unique virus-derived particles that can kill human blood cancer cells in the laboratory and eradicate the disease in mice with few side effects.
While Dr. Bell and his colleagues have been investigating replicating viruses for the treatment of solid cancers for many years, with very promising results, this is the first major success they have had treating blood cancer (leukemia). It is also the first success they have had using a non-replicating virus-derived particle as opposed to a replicating virus.
“Our research indicated that a replicating virus might not be the safest or most effective approach for treating leukemia, so we decided to investigate whether we could make virus-derived particles that no longer replicate but still kill cancer,” said Dr. Conrad, a hematologist conducting research in the Blood and Marrow Transplant Program at The Ottawa Hospital, and currently completing his PhD at OHRI and uOttawa in the Department of Cellular and Molecular Medicine. “We were delighted to see that this novel therapy was very safe at high doses, and worked extremely well in our laboratory leukemia models. We hope to test this in patients in the near future.”
The researchers used a specific method and dose of UV light to transform regular replicating viruses into unique particles that could no longer replicate and spread, but could still enter cancer cells efficiently, kill them and stimulate a strong immune response against the cancer. These particles were able to kill multiple forms of leukemia in the laboratory, including samples taken from local patients who had failed all other therapies. Normal blood cells were not affected. This novel treatment was also successful in mouse models of leukemia. In fact, 80 per cent of the mice that received the therapy had markedly prolonged survival and 60 per cent were eventually cured, while all of the untreated mice died of their leukemia within 20 days.
“Leukemia is a devastating disease that can be very difficult to treat, and new therapies are urgently needed,” said Dr. Conrad. “While we’re still at the early stages of this research, I think this therapy holds a lot of promise because it appears to have a potent, long-lasting effect on leukemia without the debilitating side effects of many cancer therapies used in the clinic right now.
The Latest on: Virus-derived particles
- Hyderabad polio virus derived from vaccine: Health minister on June 16, 2016 at 4:10 am
The OPV contains live viruses excreted by babies given the vaccine and these get into the sewage. While OPV protects children, tThese excreted particles can at times regain neuro-virulence (capacity of a micro-organism to cause disease of nervous system ... […]
- Viral con foils drug-resistant microbes, may nix need for poop transplants on February 25, 2016 at 12:46 pm
They found it in a molecule called resiquimod (R848), which is a previously created, synthetic chemical that mimics virus-derived, single-stranded RNA ... A particular concern is that the virus-mimicking particles could spur overblown immune responses ... […]
- Virus-Derived Particles Target Blood Cancer on August 15, 2013 at 8:25 am
Ottawa researchers have developed unique virus-derived particles that can kill human blood cancer cells in the laboratory and eradicate the disease in mice with few side effects. While Dr. Bell and his colleagues have been investigating replicating viruses ... […]
- Researchers Use Non-Replicating Virus Particles to Kill Leukemia Cells on August 13, 2013 at 8:16 am
“Our research indicated that a replicating virus might not be the safest or most effective approach for treating leukemia, so we decided to investigate whether we could make virus-derived particles that no longer replicate but still kill cancer,” said ... […]
- Health Canada pulls distribution of Novartis flu vaccines on October 27, 2012 at 4:50 am
The decision relates to the discovery by the company of tiny clumps of virus particles in some batches of flu vaccines ... "The aggregate proteins are predominantly influenza virus-derived (mainly hemagglutinin), all normal and necessary components of ... […]
- Spleen necrosis virus-derived C-type retroviral vectors for gene transfer to quiescent cells on March 7, 2000 at 4:00 pm
We show that SNV vector particles containing a NLS are capable of transducing ... Plasmid constructs are indicated by the letter p (e.g. pRD136) to distinguish them from the virus derived from the plasmid construct (e.g. RD136). The SNV MA mutants were ... […]
- Structure of Enzyme in AIDS Virus Is Identified on February 15, 1989 at 4:00 pm
Material Stays in Cell Retrovirus particles contain genes in the form of RNA ... Then, a second viral enzyme, an integrase, incorporates the virus-derived DNA into the genetic material of the infected cell. The virus material can then stay within the ... […]
via Google News and Bing News